FindTrial
Sign In

Detection of Gene Mutation Spectrum in de novo elderly AML Patients with Normal Karyotype

Detection of Gene Mutation Spectrum in de novo elderly AML Patients with Normal Karyotype

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029534
Enrollment
Unknown
Registered
2020-02-03
Start date
2020-01-01
Completion date
Unknown
Last updated
2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Interventions

case series:None

Sponsors

The First affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 89 Years

Inclusion criteria

Inclusion criteria: (1) Informed consent signed by the patient or legally authorized representative; (2) Conformed acute myeloid leukemia according to WHO classification, being identified as normal karyotype; (3) Aged 15–60 years;

Exclusion criteria

Exclusion criteria: those who are identified as PML-RARa positive, CBFßMYH11 positive or AML1-ETO positive

Design outcomes

Primary

MeasureTime frame
gene mutation;—

Countries

China

Contacts

Public ContactJie Jin

The First affiliated Hospital, School of Medicine, Zhejiang University

jiej0503@163.com+86 13505716779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026